



PRESS RELEASE, May 19, 2020

SelectImmune Pharma named by *Affärsvärlden* as best IPO in the “Quality” category

On May 18, *Affärsvärlden* presented the winners of its competition “IPO of the Year,” which includes micro-entities that were listed in 2019. SelectImmune Pharma was named winner in the “Quality” category.

Each year, *Affärsvärlden* awards prizes to the best listings in the categories of “Share price performance” and “Quality.” In the “Quality” category, companies are primarily assessed on their readiness to go public, but also on their share price performance. Any issue that is deemed troubling is given a flag.

This year, SelectImmune Pharma has been named the winner in the “Quality” category with the motivation being that the jury only identified one flag, which is considered a mark of excellence for a micro-entity. For the IPO, Arctic Securities provided advisory services in collaboration with the company’s financial and legal experts.

“We are proud of this distinction and grateful for all of the work carried out by the Board of Directors, our financial and legal advisors and our employees. The IPO establishes the platform required to continue successful research into alternatives to antibiotics – a field that will likely be of great significance in the near future,” says Jakob Testad, acting CEO of SelectImmune Pharma AB.

For more information, please contact:

Catharina Svanborg

Chairman of the Board, SelectImmune Pharma AB

Tel: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Jakob Testad

Acting CEO, SelectImmune Pharma AB

Tel: +46 708 48 42 10

E-mail: jakob.testad@selectimmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.